JP2020521798A5 - - Google Patents

Info

Publication number

JP2020521798A5

JP2020521798A5 JP2019566227A JP2019566227A JP2020521798A5 JP 2020521798 A5 JP2020521798 A5 JP 2020521798A5 JP 2019566227 A JP2019566227 A JP 2019566227A JP 2019566227 A JP2019566227 A JP 2019566227A JP 2020521798 A5 JP2020521798 A5 JP 2020521798A5

Authority

JP

Japan

Prior art keywords

antibody

seq

use according

medicament

cancer

Prior art date

2018-05-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003862 glucocorticoid Substances 0.000 claims description 26
• 206010028980 Neoplasm Diseases 0.000 claims description 22
• 201000011510 cancer Diseases 0.000 claims description 14
• 239000000427 antigen Substances 0.000 claims description 9
• 102000036639 antigens Human genes 0.000 claims description 9
• 108091007433 antigens Proteins 0.000 claims description 9
• 206010061218 Inflammation Diseases 0.000 claims description 6
• 230000002411 adverse Effects 0.000 claims description 6
• 230000004054 inflammatory process Effects 0.000 claims description 6
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 229960003852 atezolizumab Drugs 0.000 claims description 4
• 230000003442 weekly effect Effects 0.000 claims description 4
• VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 2
• 206010006187 Breast cancer Diseases 0.000 claims description 2
• 208000026310 Breast neoplasm Diseases 0.000 claims description 2
• 206010009944 Colon cancer Diseases 0.000 claims description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
• 239000005557 antagonist Substances 0.000 claims description 2
• 206010017758 gastric cancer Diseases 0.000 claims description 2
• 201000005202 lung cancer Diseases 0.000 claims description 2
• 208000020816 lung neoplasm Diseases 0.000 claims description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims description 2
• 229960004584 methylprednisolone Drugs 0.000 claims description 2
• 201000002528 pancreatic cancer Diseases 0.000 claims description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
• 229960004618 prednisone Drugs 0.000 claims description 2
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
• 230000002265 prevention Effects 0.000 claims description 2
• 201000011549 stomach cancer Diseases 0.000 claims description 2
• 239000003814 drug Substances 0.000 claims 22
• 229940079593 drug Drugs 0.000 claims 3
• 238000000034 method Methods 0.000 description 20
• 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 2